Membership of the Bisphosphonates Working Group
This guideline was developed by a multidisciplinary working group convened by NBOCC*.
|Dr Nick Pavlakis||Medical Oncologist (Chair)|
|Dr Peter Barry||Surgeon|
|Ms Denice Bassanelli||Consumer Representative|
|Ms Sholeh Boyle||Specialist Breast Nurse|
|Dr Roslyn Drummond||Radiation Oncologist|
|Dr Belinda Kiely||Medical Oncologist|
|Ms Jenny Macindoe||Breast Care Nurse Coordinator|
|Dr Katrina Moore||Surgeon|
|Ms Marlene Parsons||Consumer Representative|
|Ms Geraldine Robertson||Consumer Representative|
|Dr Bronwyn Stuckey||Endocrinologist|
Cancer Australia acknowledges the Breast Cancer Guideline Update Steering Committee, chaired by Dr Catherine Shannon, for their input into the development of this guideline.
Cancer Australia staff
|Ms Sue Sinclair||General Manager|
|Ms Ornella Care||Program Manager|
|Ms Fleur Webster||Program Manager|
|Ms Emma Lonsdale||Project Officer|
|Dr Anne Nelson||Evidence Review and Research Leader|
|Ms Rosemary Wade||Senior Project Officer – Research|
* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
Cancer Australia acknowledges those who gave their time to provide comment on the draft guideline recommendations as part of the external review process.
Topic-specific guideline development process
Priority topic areas for Cancer Australia guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded. The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.
The National Breast Cancer Foundation provided funding for the development and production of this guideline.